Emerging genomic technologies and the concept of personalized medicine: An overview of ethical, legal and social implications

Glinskii, Victoria G.; Glinsky, Gennadi V.

doi:10.4161/cc.6476

Cited by 3 publications

(3 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is generally expected that molecular subtyping of tumors will eventually lead to more specific treatment regimens per subtype. This approach is generally considered as a new treatment paradigm in oncology and referred to as personalized medicine . One important type of research in this field is high throughput drug screening.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Raman spectroscopy can discriminate distinct glioma subtypes as defined by RNA expression profiling

Jachtenberg

Schut

French

et al. 2013

J Raman Spectroscopy

View full text Add to dashboard Cite

Raman spectroscopy is a molecular spectroscopic technique that can measure the molecular composition of tissue samples within seconds without any extraction processes or dyes. In microbiology, Raman spectroscopy is used to identify bacteriae. In glioblastoma tissue, it was reported that necrosis, normal brain and tumor can be discriminated using Raman spectroscopy. Therefore, we hypothesized that Raman spectroscopy could discriminate glioblastoma tissue from different glioma subtypes defined by RNA expression profiling. We analyzed 20 glioma samples from two distinct molecular subtypes. Both subtypes consisted of glioblastoma samples showing a variety in glioma grading and typing. The Raman spectroscopic results could be grouped in two distinct clusters in an unsupervised cluster analysis. Further analysis of these clusters showed that they were fully congruent with the two clusters as defined by RNA expression profiling. Conclusion: our results demonstrate that Raman spectroscopy can discriminate between different molecular subtypes of glioma and, therefore, may prove to be a valuable tool in in vitro cancer research. Copyright © 2013 John Wiley & Sons, Ltd.

show abstract

Section: Introductionmentioning

confidence: 99%

“…This approach is generally considered as a new treatment paradigm in oncology and referred to as personalized medicine. [6,7,26,27] One important type of research in this field is high throughput drug screening. This approach enables testing of the large numbers of available targeted drugs on distinct tumor (sub-) types.…”

Section: Introductionmentioning

confidence: 99%

Raman spectroscopy can discriminate distinct glioma subtypes as defined by RNA expression profiling

Jachtenberg

Schut

French

et al. 2013

J Raman Spectroscopy

View full text Add to dashboard Cite

show abstract

“…Inasmuch as the personalized medicine management of infectious diseases principally targets the genomic components of the pathogen(s), the determination of the pharmacogenetic and/or immunogenetic profiles of a patient might provide the physician with additional clues to adequately fight an infection, we do not believe that infectious diseases personalized medicine will be hampered by the social issues and ethical debate that eventually led to the approval of Genetic Information Nondiscrimination Act (GINA) of 2008 by the United States legislative bodies [ 123 , 124 , 125 ].…”

Section: Regulatory Ethical and Financial Challenges To Poc Or Nmentioning

confidence: 99%

Infectious Disease Management through Point-of-Care Personalized Medicine Molecular Diagnostic Technologies

Bissonnette

Bergeron

2012

JPM

View full text Add to dashboard Cite

Infectious disease management essentially consists in identifying the microbial cause(s) of an infection, initiating if necessary antimicrobial therapy against microbes, and controlling host reactions to infection. In clinical microbiology, the turnaround time of the diagnostic cycle (>24 hours) often leads to unnecessary suffering and deaths; approaches to relieve this burden include rapid diagnostic procedures and more efficient transmission or interpretation of molecular microbiology results. Although rapid nucleic acid-based diagnostic testing has demonstrated that it can impact on the transmission of hospital-acquired infections, we believe that such life-saving procedures should be performed closer to the patient, in dedicated 24/7 laboratories of healthcare institutions, or ideally at point of care. While personalized medicine generally aims at interrogating the genomic information of a patient, drug metabolism polymorphisms, for example, to guide drug choice and dosage, personalized medicine concepts are applicable in infectious diseases for the (rapid) identification of a disease-causing microbe and determination of its antimicrobial resistance profile, to guide an appropriate antimicrobial treatment for the proper management of the patient. The implementation of point-of-care testing for infectious diseases will require acceptance by medical authorities, new technological and communication platforms, as well as reimbursement practices such that time- and life-saving procedures become available to the largest number of patients.

show abstract

Gene expression variations: potentialities of master regulator polymorphisms in colorectal cancer risk

Pardini¹,

Naccarati²,

Vodicka³

et al. 2012

Mutagenesis

View full text Add to dashboard Cite

Colorectal cancer (CRC) is one of the most common cancers worldwide with a peak of incidence in industrialised countries. It is a complex disease related to environmental and genetic risk factors. Low-penetrance genetic variations contribute significantly to sporadic and familial form of CRC. Genome-wide association studies (GWAS) have uncovered numerous robust associations between common variants and CRC risk; only a few of those were protein altering non-synonymous polymorphisms. One of the hypotheses is that non-coding and intergenic variants may change the expression levels of one or several target genes and, thus, account for a fraction of phenotypic differences, including susceptibility to CRC. Such genetic variations have been detected as expression quantitative loci (eQTLs) that show linkage/association to a large number of genes and have been defined as "master regulators of transcription". In the present work, we overview the potentialities to use results from GWAS and eQTL studies in the identification as well as investigation of master regulators in CRC susceptibility.

show abstract

Emerging genomic technologies and the concept of personalized medicine: An overview of ethical, legal and social implications

Cited by 3 publications

References 10 publications

Raman spectroscopy can discriminate distinct glioma subtypes as defined by RNA expression profiling

Raman spectroscopy can discriminate distinct glioma subtypes as defined by RNA expression profiling

Infectious Disease Management through Point-of-Care Personalized Medicine Molecular Diagnostic Technologies

Gene expression variations: potentialities of master regulator polymorphisms in colorectal cancer risk

Contact Info

Product

Resources

About